Anakinra — Drug Intelligence | 23 EU Trials

Filter these 23 trials by condition, phase, country and more.

Open in Search →

23 Registered trials

8 Recruiting

9 Completed trials

13 Sponsors

20 Countries

Phase III

Phase II

Phase III: 7 Phase II/III: 1 Phase II: 10 Phase I/II: 2 Phase IV: 1 Phase I: 1 Phase I (FiH): 1

Oversight events:

4 serious breaches 1 temporary halt 1 unexpected event 1 corrective measure across 5 trials

View oversight register →

Indications tested

Pericarditis 1 B-cell lymphoma refractory 1 Neuroblastoma 1 Pancreas transplant 1 Kawasaki's disease 1 Type 1 diabetes mellitus 1 Ewing's sarcoma 1 Osteosarcoma 1 Sepsis 1 Breast cancer 1 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 6 Genmab A/S 5 Ospedale San Raffaele S.r.l. 2 Azienda Sanitaria Universitaria Friuli Centrale 1 Centre Hospitalier Universitaire De Nantes 1 Giannina Gaslini Institute For Scientific Hospitalization And Care 1 Hellenic Institute For The Study Of Sepsis 1 Prinses Maxima Centrum voor Kinderoncologie B.V. 1 Radboud universitair medisch centrum Stichting 1 Stichting Radboud University Medical Center 1 Universitaet Muenster 1 Universitaetsklinikum Heidelberg AöR 1

All trials

23 total

Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study. Pending

2024-518125-15-00 Phase II 1 country Azienda Sanitaria Universitaria Friuli Centrale
ESTIS trial: Early Stop of targeted Treatment in children with Systemic JIA. Pending

2024-518684-35-00 Phase IV 1 country Universitair Medisch Centrum Utrecht
PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending

2025-521371-31-00 Phase II 1 country Assistance Publique Hopitaux De Paris
ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS Pending

2025-521478-32-00 Phase III 1 country Assistance Publique Hopitaux De Paris
THRILL: Treat Hyperinflammation in child oncology study Pending

2025-524541-27-00 Phase II 1 country Prinses Maxima Centrum voor Kinderoncologie B.V.
IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO) Pending

2025-524834-24-00 Phase I/II 1 country Centre Hospitalier Universitaire De Nantes
Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: t… Recruiting

2023-508123-12-00 Phase II/III 4 countries Hellenic Institute For The Study Of Sepsis
ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RET… Recruiting

2024-516244-25-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial Recruiting

2024-517230-17-00 Phase II 1 country Stichting Radboud universitair medisch centrum
Randomized controlled trial in patients on long-term colchicine with colchicine-resistant familial Mediterranean fever (FMF) to evaluate the… Recruiting

2023-506721-11-00 Phase III 1 country Assistance Publique Hopitaux De Paris
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers Recruiting

2022-501725-21-00 Phase I 1 country Universitaet Muenster
Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroi… Recruiting

2023-504756-96-00 Phase III 1 country Giannina Gaslini Institute For Scientific Hospitalization And Care
Targeted therapy with anakinra for dilated cardiomyopathy: phase IIa randomized double blind monocentric clinical trial to evaluate the effi… Recruiting

2024-514861-21-00 Phase II 1 country Ospedale San Raffaele S.r.l.
A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration o… Recruiting

2023-510376-31-00 Phase II 1 country Universitaetsklinikum Heidelberg AöR
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Phase III 15 countries Genmab A/S
Effect of different drugs on the immune response during inflammation: the DEDICATE-LPS study Ended

2023-506556-24-00 Phase II 1 country Stichting Radboud University Medical Center
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA. Ended

2023-504832-16-00 Phase II 8 countries Genmab A/S
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 Phase III 13 countries Genmab A/S
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended

2023-504805-35-00 Phase I/II 10 countries Genmab A/S
A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma Ended

2023-504802-12-00 Phase I (FiH) 9 countries Genmab A/S
PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease Ended

2024-513647-86-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease… Ended

2024-514347-28-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo-controlled, randomized clinical trial to evaluate the e… Ended

2024-515472-13-00 Phase II 1 country Ospedale San Raffaele S.r.l.

Showing 1–23 of 23 trials

← All drugs A–Z